Long-term safety of monthly zoledronic acid therapy beyond 1 year in patients with advanced cancer involving bone (LoTESS): A multicentre prospective phase 4 study. [electronic resource]
Producer: 20180907Description: e12638 p. digitalISSN:- 1365-2354
- Aged
- Aged, 80 and over
- Bone Density Conservation Agents -- adverse effects
- Bone Diseases -- drug therapy
- Diphosphonates -- adverse effects
- Female
- Humans
- Imidazoles -- adverse effects
- Kaplan-Meier Estimate
- Longitudinal Studies
- Male
- Middle Aged
- Neoplasms -- complications
- Prospective Studies
- Zoledronic Acid
No physical items for this record
Publication Type: Clinical Trial, Phase IV; Journal Article; Multicenter Study; Observational Study
There are no comments on this title.
Log in to your account to post a comment.